This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
_256_384.jpg)
The focus of this year’s challenge is to find solutions within Covid management and treatment of cardiovascular, renal, neuro, cancer and lung diseases
Serum buys 50 per cent stake in Indian joint venture of SCHOTT Kaisha
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
The project is a collaboration between IIT Delhi and AIIMS
Investment of Rs 235 crores to add 411 beds in the next 18 months
The company reports revenue growth of 26% and PAT growth of 21% YoY
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
The transaction improves patient experience, patient outcomes and aims to reduce health care costs
Subscribe To Our Newsletter & Stay Updated
